HISPRIL Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Hispril, and when can generic versions of Hispril launch?
Hispril is a drug marketed by Glaxosmithkline and is included in one NDA.
The generic ingredient in HISPRIL is diphenylpyraline hydrochloride. There are two drug master file entries for this compound. Additional details are available on the diphenylpyraline hydrochloride profile page.
Summary for HISPRIL
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 48 |
Patent Applications: | 2,629 |
Formulation / Manufacturing: | see details |
DailyMed Link: | HISPRIL at DailyMed |
Anatomical Therapeutic Chemical (ATC) Classes for HISPRIL
US Patents and Regulatory Information for HISPRIL
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Glaxosmithkline | HISPRIL | diphenylpyraline hydrochloride | CAPSULE, EXTENDED RELEASE;ORAL | 011945-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |